IMM 6.90% 27.0¢ immutep limited

my report listening to the investor conference, page-19

  1. 459 Posts.
    lightbulb Created with Sketch. 7
    For those who are genuinely interested in Prima and the recent presentation, I add a summary below which I created for myself after attending for future reference. This summary is in my words and how I recall it:

    1. Orphan Drug Status is applied for separately and after IND is granted. Expecting to submit and have Orphan Drug Status granted within next six months;

    2. Expecting to commence Phase IIb trials by the end of this year (2009);

    3. The A$25.5m SpringTree funding was estimated at 2.5 times the amount required to complete phase IIb trials. This amount of funding was arranged to remove any hurdles that may arise and ensure market confidence remained and the share price wasn't unecessarily forced down as it has been previously;

    4. Prima are not required to use all or any of the currently arranged funding facilities with Fortrend and SpringTree;

    5. Prima can request/apply for funding on better terms with SpringTree or look elsewhere whenever they like;

    6. IIb trials expected to take two years;

    7. Interim data expected after twelve months into IIb trials (i.e. about 18months time);

    8. Phase III trials will start before phase IIb trials are completed, with these trials overlapping each other;

    9. Prima have a number of Patents which cover the process of creating and administering Cvac. Some patents expire in 2014 while others expire in 2018. Martin Rogers further explained that being first to market would be a huge advantage for Prima, even if there was a short patent life (e.g. 1.5 to 2 years). This is because this process is so complex, Oncologist would be reluctant to recommend/prescribe alternate generic versions of this treatment to patients. E.g. This is a cancer vaccine, not an over the counter Viagra; (they are expecting Orphan Status though which will extend patent life)

    10. Dendreon would not be able to move into Ovarian Cancer treatment with Provenge as their patent is specifically related to a protein or substance located only in the prostate;

    11. Cvac is the closest Ovarian Cancer treatment to commercialisation. No other treatment apart from surgery & Chemotherapy is available.

    12. There is potential for Cvac to be used by Oncologists for other cancer treatments, not just Ovarian Cancer. Prima will only focus on development and trials with Ovarian Cancer, however there is nothing stopping Oncologist using Cvac for other Cancers once it receives approval.

    13. Those shareholders who are concerned about dilution are not thinking about the need to bring this treatment to market. Management are aware of dilution.

    14. Regarding the two patients being treated in Melbourne. One patient was too far progressed with their disease and had no immune system. This person had had multiple treatments with Chemo-therapy and passed away after only one injection with Cvac. The other patient is still being treated.

    15. The most likely outcome should be a partnering with or takeover by a large Pharmaceutical/Drug Manufacturer, however Prima are not averse to taking Cvac to market themselves, like Dendreon with Provenge.

    There were further discussions which reflected positively on prima and the potential which exists for investors. I am choosing not to add this for my own reasons.

    I am becoming increasingly disilusioned with the petty and pointless posts regarding Prima on HC. There are some posters who I would even label as toxic. For example, criticising posts without understanding what has been said and without a balanced viewpoint (i.e. knowledge of product & processes) occurs too often. And suggestions that it is not important to know what Cvac is about and how it works is astounding. Lets get real people, if you have nothing to say, don't post. Yes, progess with Cvac will take time; yes there will be a large number of shares on issue; and yes there is risk as this is far from a done deal. Now that we have that out of the way, can we see some informative, interesting and most of all realistic posts!

    And NO, I will not be participating in any argumentative dribble about what I have posted. If you don't like it, then disregard it. Believing Cvac will work is my perogative, but I do not slam it down peoples throats.

    Regards
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
27.0¢
Change
-0.020(6.90%)
Mkt cap ! $392.7M
Open High Low Value Volume
29.0¢ 29.0¢ 27.0¢ $569.8K 2.076M

Buyers (Bids)

No. Vol. Price($)
8 706076 27.0¢
 

Sellers (Offers)

Price($) Vol. No.
27.5¢ 100000 1
View Market Depth
Last trade - 16.10pm 07/11/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.